Pharmaceuticals

Global Roxadustat Market Analysis 2025–2029: Opportunities for Strategic Growth

November 11, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Was The Roxadustat Market Worth In 2025, And What Is Its Anticipated Value By 2029?

The market for roxadustat has experienced robust expansion recently. Projections indicate it will expand from $6.44 billion in 2024 to reach $6.86 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 6.5%. Historically, this expansion can be linked to factors such as regulatory clearances in key markets, impressive outcomes from clinical trials, the rising incidence of chronic kidney disease, enhanced understanding of anemia management, and governmental backing for anemia therapies.

The roxadustat market is anticipated to experience substantial expansion over the upcoming years. It is projected to reach $8.95 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.9%. This projected growth stems from several factors, including continuous research into novel indications, a rise in healthcare spending, the increasing need for non-injectable anemia therapies, broadening reimbursement policies, and an expanding elderly demographic. Key developments expected during this forecast timeframe encompass a move towards oral anemia treatments, heightened rivalry from other therapeutic options, more extensive licensing agreements, increased capital allocation for hypoxia-inducible factor research, and a greater emphasis on patient-focused treatment strategies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21280&type=smp

What Are The Main Drivers Boosting The Roxadustat Industry’s Expansion?

The increasing prevalence of individuals with chronic kidney disease (CKD) is projected to boost the growth of the Roxadustat market. CKD is a long-term ailment where kidneys gradually lose their functional capacity, frequently leading to renal failure if left unaddressed. The global number of people suffering from CKD is expanding due to factors like an aging population, rising incidence of diabetes and hypertension, and unhealthy lifestyle choices. Roxadustat helps manage this condition by stimulating erythropoietin production, which increases red blood cell count and helps combat anemia commonly associated with CKD, thus enhancing overall kidney function and patient quality of life. For example, a report released in December 2024 by the Australian Institute of Health and Welfare (AIHW), an Australia-based government agency, showed that chronic kidney disease mortality rates saw a modest annual increase, specifically 4.2% in 2021 and 6.2% in 2022. Hence, the increasing number of individuals with chronic kidney disease (CKD) is a primary driver for the expansion of the Roxadustat market.

How Is The Roxadustat Market Classified Into Different Segments?

The roxadustat market covered in this report is segmented –

1) By Type: 20mg, 50mg

2) By Product Formulation: Oral Tablets

3) By Distribution Channel: Hospitals, Specialty Pharmacies, Dialysis Centers

4) By End-User Application: Chronic Kidney Disease-Associated Anemia, Other Anemia Conditions

What Trends Are Expected To Drive The Roxadustat Market?

Leading companies in the Roxadustat market are pursuing reimbursement through the high-tech drugs scheme to ensure wider patient access by mitigating financial barriers, thereby enhancing market adoption and showcasing the economic benefit of their innovative treatments. This high-tech drugs scheme is a government-managed initiative, primarily in Ireland, that offers reimbursement for the dispensing of expensive, highly specialized medications typically prescribed within hospital environments. As an illustration, in September 2022, Astellas Pharma Company Ltd., a US-based pharmaceutical company, announced that its product EVRENZO (Roxadustat) was granted reimbursement under the High-Tech Drugs Scheme in Ireland. Roxadustat is the initial orally administered hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor in its class to be both licensed and reimbursed in Ireland. The outcomes demonstrated that Roxadustat was effective in reaching and sustaining target hemoglobin levels (10-12g/dL) in patients suffering from symptomatic anemia of CKD, independent of their dialysis status and any prior ESA treatment.

Who Are The Core Companies Influencing The Roxadustat Market Landscape?

Major companies operating in the roxadustat market are AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy’s Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., GLR Innovations, Suzhou Biosyntech Co. Ltd., Shanvr Life Sciences Pvt. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/roxadustat-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Roxadustat Market?

North America was the largest region in the Roxadustat market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roxadustat market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Roxadustat Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21280&type=smp

Browse Through More Reports Similar to the Global Roxadustat Market 2025, By The Business Research Company

Anemia And Other Blood Disorder Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Chemotherapy Induced Anemia Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Diabetic Kidney Disease Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/diabetic-kidney-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795